Article Text

Download PDFPDF
STN stimulation and neuroprotection in Parkinson’s disease—when beautiful theories meet ugly facts
  1. P C Warnke
  1. Correspondence to:
 Professor Peter C Warnke
 The University of Liverpool, Department of Neuroscience, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L97LJ, UK; p.c.warnkeliv.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

STN stimulation does not halt progression of Parkinson’s disease

Repeated claims have been made that inactivation of the subthalamic nucleus (STN) is a neuroprotective measure.1–3 It was postulated that by suppression of the glutamatergic STN, glutamate mediated excitotoxicity exerted on the substantia nigra could be reduced, if not abolished. The paper by Hilker et al in this issue (see page 1217) deals with this topic by looking longitudinally at patients who have undergone successful STN stimulation. The investigators have taken the approach of using objective functional imaging employing 18F-DOPA positron emission tomography (PET), an established objective measure of biological progression in Parkinson’s disease, which was then correlated with clinical progression. They were able to show convincingly that STN stimulation did not halt the progression of Parkinson’s disease.

They have also shown …

View Full Text

Footnotes

  • Competing interests: none declared

Linked Articles